Literature DB >> 25596265

Excess of heme induces tissue factor-dependent activation of coagulation in mice.

Erica M Sparkenbaugh1, Pichika Chantrathammachart2, Shaobin Wang1, Will Jonas1, Daniel Kirchhofer3, David Gailani4, Andras Gruber5, Raj Kasthuri1, Nigel S Key1, Nigel Mackman1, Rafal Pawlinski6.   

Abstract

An excess of free heme is present in the blood during many types of hemolytic anemia. This has been linked to organ damage caused by heme-mediated oxidative stress and vascular inflammation. We investigated the mechanism of heme-induced coagulation activation in vivo. Heme caused coagulation activation in wild-type mice that was attenuated by an anti-tissue factor antibody and in mice expressing low levels of tissue factor. In contrast, neither factor XI deletion nor inhibition of factor XIIa-mediated factor XI activation reduced heme-induced coagulation activation, suggesting that the intrinsic coagulation pathway is not involved. We investigated the source of tissue factor in heme-induced coagulation activation. Heme increased the procoagulant activity of mouse macrophages and human PBMCs. Tissue factor-positive staining was observed on leukocytes isolated from the blood of heme-treated mice but not on endothelial cells in the lungs. Furthermore, heme increased vascular permeability in the mouse lungs, kidney and heart. Deletion of tissue factor from either myeloid cells, hematopoietic or endothelial cells, or inhibition of tissue factor expressed by non-hematopoietic cells did not reduce heme-induced coagulation activation. However, heme-induced activation of coagulation was abolished when both non-hematopoietic and hematopoietic cell tissue factor was inhibited. Finally, we demonstrated that coagulation activation was partially attenuated in sickle cell mice treated with recombinant hemopexin to neutralize free heme. Our results indicate that heme promotes tissue factor-dependent coagulation activation and induces tissue factor expression on leukocytes in vivo. We also demonstrated that free heme may contribute to thrombin generation in a mouse model of sickle cell disease. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25596265      PMCID: PMC4349268          DOI: 10.3324/haematol.2014.114728

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  34 in total

1.  Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin.

Authors:  S A Gregory; J H Morrissey; T S Edgington
Journal:  Mol Cell Biol       Date:  1989-06       Impact factor: 4.272

2.  Low levels of tissue factor are compatible with development and hemostasis in mice.

Authors:  G C Parry; J H Erlich; P Carmeliet; T Luther; N Mackman
Journal:  J Clin Invest       Date:  1998-02-01       Impact factor: 14.808

3.  Heme is a potent inducer of inflammation in mice and is counteracted by heme oxygenase.

Authors:  F A Wagener; A Eggert; O C Boerman; W J Oyen; A Verhofstad; N G Abraham; G Adema; Y van Kooyk; T de Witte; C G Figdor
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

Review 4.  Hemopexin: structure, function, and regulation.

Authors:  Emanuela Tolosano; Fiorella Altruda
Journal:  DNA Cell Biol       Date:  2002-04       Impact factor: 3.311

5.  Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin.

Authors:  Anna Solovey; Rahn Kollander; Arun Shet; Liming C Milbauer; Stephana Choong; Angela Panoskaltsis-Mortari; Bruce R Blazar; Robert J Kelm; Robert P Hebbel
Journal:  Blood       Date:  2004-04-08       Impact factor: 22.113

Review 6.  Role of tissue factor in haemostasis, thrombosis, angiogenesis and inflammation: lessons from low tissue factor mice.

Authors:  Rafal Pawlinski; Brian Pedersen; Jonathan Erlich; Nigel Mackman
Journal:  Thromb Haemost       Date:  2004-09       Impact factor: 5.249

7.  Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia.

Authors:  Rafal Pawlinski; Brian Pedersen; Gernot Schabbauer; Michael Tencati; Todd Holscher; William Boisvert; Patricia Andrade-Gordon; Rolf Dario Frank; Nigel Mackman
Journal:  Blood       Date:  2003-10-23       Impact factor: 22.113

8.  Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease.

Authors:  Maria L Jison; Peter J Munson; Jennifer J Barb; Anthony F Suffredini; Shefali Talwar; Carolea Logun; Nalini Raghavachari; John H Beigel; James H Shelhamer; Robert L Danner; Mark T Gladwin
Journal:  Blood       Date:  2004-03-18       Impact factor: 22.113

9.  Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes.

Authors:  Arun S Shet; Omer Aras; Kalpna Gupta; Mathew J Hass; Douglas J Rausch; Nabil Saba; Louann Koopmeiners; Nigel S Key; Robert P Hebbel
Journal:  Blood       Date:  2003-06-12       Impact factor: 22.113

10.  Functional tissue factor is entirely cell surface expressed on lipopolysaccharide-stimulated human blood monocytes and a constitutively tissue factor-producing neoplastic cell line.

Authors:  T A Drake; W Ruf; J H Morrissey; T S Edgington
Journal:  J Cell Biol       Date:  1989-07       Impact factor: 10.539

View more
  31 in total

Review 1.  New insights into sickle cell disease: mechanisms and investigational therapies.

Authors:  Gregory J Kato
Journal:  Curr Opin Hematol       Date:  2016-05       Impact factor: 3.284

Review 2.  Neutrophils: back in the thrombosis spotlight.

Authors:  Denis F Noubouossie; Brandi N Reeves; Brian D Strahl; Nigel S Key
Journal:  Blood       Date:  2019-03-21       Impact factor: 22.113

3.  Antithrombotic effects of heme-degrading and heme-binding proteins.

Authors:  Karl A Nath; Joseph P Grande; John D Belcher; Vesna D Garovic; Anthony J Croatt; Matthew L Hillestad; Michael A Barry; Meryl C Nath; Raymond F Regan; Gregory M Vercellotti
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-01-31       Impact factor: 4.733

4.  Developing new pharmacotherapeutic approaches to treating sickle-cell disease.

Authors:  Marilyn J Telen
Journal:  ISBT Sci Ser       Date:  2016-11-15

Review 5.  Intravascular hemolysis and the pathophysiology of sickle cell disease.

Authors:  Gregory J Kato; Martin H Steinberg; Mark T Gladwin
Journal:  J Clin Invest       Date:  2017-03-01       Impact factor: 14.808

6.  High molecular weight kininogen contributes to early mortality and kidney dysfunction in a mouse model of sickle cell disease.

Authors:  Erica M Sparkenbaugh; Malgorzata Kasztan; Michael W Henderson; Patrick Ellsworth; Parker Ross Davis; Kathryn J Wilson; Brandi Reeves; Nigel S Key; Sidney Strickland; Keith McCrae; David M Pollock; Rafal Pawlinski
Journal:  J Thromb Haemost       Date:  2020-08-27       Impact factor: 5.824

7.  Red Blood Cell Adhesion to Heme-Activated Endothelial Cells Reflects Clinical Phenotype in Sickle Cell Disease.

Authors:  Erdem Kucukal; Anton Ilich; Nigel S Key; Jane A Little; Umut A Gurkan
Journal:  Am J Hematol       Date:  2018-06-15       Impact factor: 10.047

8.  Protease-Activated Receptor 1 Enhances Poly I:C Induction of the Antiviral Response in Macrophages and Mice.

Authors:  Silvio Antoniak; Kohei Tatsumi; Michael Bode; Swetha Vanja; Julie C Williams; Nigel Mackman
Journal:  J Innate Immun       Date:  2016-11-08       Impact factor: 7.349

9.  Sustained treatment of sickle cell mice with haptoglobin increases HO-1 and H-ferritin expression and decreases iron deposition in the kidney without improvement in kidney function.

Authors:  Patricia A Shi; Erika Choi; Narendranath R Chintagari; Julia Nguyen; Xinhua Guo; Karina Yazdanbakhsh; Narla Mohandas; Abdu I Alayash; Elizabeth A Manci; John D Belcher; Gregory M Vercellotti
Journal:  Br J Haematol       Date:  2016-08-10       Impact factor: 6.998

Review 10.  Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies.

Authors:  Denis Noubouossie; Nigel S Key; Kenneth I Ataga
Journal:  Blood Rev       Date:  2015-12-24       Impact factor: 8.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.